Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-203 in advanced solid tumours
NCT02264418Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Sep 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of aur109 in solid tumor (2 arms), sponsored by Orion Corporation. Primary endpoint: Number of adverse events at 6 months. Started Sep 2014; status: completed.
02
Drugs
aur109
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02264418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264418.